# Gefitinib and Sirolimus in Treating Patients With Recurrent or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer

> **NCT00098462** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Jonsson Comprehensive Cancer Center**

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** gefitinib
- **DRUG:** sirolimus

## Key facts

- **NCT ID:** NCT00098462
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2004-10
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Withdrawn as study never opened
- **Last updated:** 2012-10-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00098462

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00098462, "Gefitinib and Sirolimus in Treating Patients With Recurrent or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00098462. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*